A. Menarini India Private Limited and A. Menarini Asia-Pacific Holdings Pte. Ltd. have divested five legacy brands in strategic therapy areas – Gastroenterology, Urology and Anti-infectives, along with the associated trademark rights to Lupin Limited.
The brands are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor).
Khaitan & Co represented Menarini entities and advised them in their divestment of the five brands and associated intellectual property rights by way of asset purchase agreements, trademark assignment agreements, novation contracts and transition services agreement. The team drafted and negotiated the transaction documents and provided closing assistance.
The core team consisted of Surbhi Kejriwal (Partner), Aadhya (Principal Associate) and Dipshikha Dhar (Associate) with assistance from the following:
Intellectual Property: Shailendra Bhandare (Partner), Sourav Dan (Principal Associate), Kinjal Parikh (Associate) and Shamika Bhagwat (Associate)
JSA advised and assisted Lupin in this acquisition deal.
The transaction team consisted of Shivpriya Nanda (Lead Partner), Zain Pandit (Partner), Gaurav G Arora (Partner), Twisha Shrivastava (Associate) and Vibhu Choubey (Associate).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4.4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia.
If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.